Synergen Development Partners
Two preclinical projects -- the FIBAC collagenase inhibitor and the HPSTI trypsin inhibitor -- are held up by "technical problems," Synergen said in a July 18 SEC filing pursuant to the company's repurchase of its R&D partnership. FIBAC, under study as a prevention of collagen decay associated with rheumatoid arthritis, corneal ulcers and solid tumor metastasis, lacks "a suitable method of delivering" the drug and "a GMP production process." HPSTI, under study as a treatment of acute pancreatitis, also lacks a suitable means of delivery and "there is concern as to whether HPSTI can reverse pancreatitis after onset of the disease," the company said. The company added that it "does not currently intend to develop" either product without a partner. The partnership's third compound, the SLPI elastase inhibitor, has moved into clinicals as a treatment for cystic fibrosis and genetic emphysema.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth